Solna, Sweden, 15 August 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, is pleased to note the announcement this morning by Inceptua AB, that it has launched Apealea® (paclitaxel micellar) in Germany.

Vivesto signed a global strategic partnership with US-based Elevar Therapeutics (“Elevar”) for the commercialization of Apealea® in March 2020 which is now being launched in Germany through Elevar’s European partner Inceptua AB (“Inceptua”).

The full announcement can be viewed on Inceptua’s website here:

For More Information: 

Vivesto AB 
Christer Nordstedt MD PhD, Acting Chief Executive Officer 
Phone: +46 018-50 54 40

Consilium Strategic Communications (For Vivesto)
Ashley Tapp
Phone: +44 (0)20 3709 5700 

About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit

About Inceptua Group
Inceptua Group is a specialty pharmaceutical company and global service partner. Inceptua Pharma commercializes and markets orphan and specialty care products and have the expertise and capabilities to supply unlicensed medicines globally. The service business units, Inceptua Clinical Trial Supply and Inceptua Early Access, support pharma and biotech companies with global clinical trial comparator sourcing, packaging, labelling, and distribution solutions and strategy, design and implementation of global early access programs (pre-approval, managed access, compassionate use). Inceptua partners with life science companies of all sizes, drawing on over 20 years of industry experience, and has global operations with local offices across Europe, North America, and Asia. Additional information is available at:

About Elevar Therapeutics
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company whose mission is to elevate treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. With offices in Utah, California, Ireland and South Korea, Elevar has multiple drug candidates in clinical development in multiple oncology therapy areas. In 2020, it licensed European distribution and commercialization of Apealea to Inceptua. Additional information is available at